



## **Press Release**

*For immediate release*

### **genOway signs a major master services agreement with the Japanese pharmaceutical leader Eisai Co., Ltd.**

**Lyon (France), April 2th 2008** – genOway (ALTERNEXT-NYSE:ALGEN ; ISIN: FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models reports the signing of a master services agreement with the Japanese pharmaceutical leader Eisai Co., Ltd.

Under the terms of this new collaborative agreement, genOway will provide its client with both customized genetically modified mouse lines tailored to the researchers' needs and ready-for-use animal models selectable from its catalogue of standardized products. This contract can be increased to include additional models. genOway has been chosen thanks to the company's expertise and capacity to create highly sophisticated animal models by means of an industrialized production process.

*"Due to our continued effort to improve our industrial platform and our aggressive in-licensing strategy in the fields of molecular, cellular biology and embryology, genOway is able to offer more and more sophisticated animal models to the big pharma companies. All these genetically modified models target a better predictive understanding of the action mechanisms during the clinical trials of their molecules",* added **Kader Thiam, VP Transgenic Technologies at genOway.**

To date, genOway makes its expertise available to over 50 major biopharmaceutical groups and 175 academic institutions, either through customized development of genetically modified research animal models or through its emerging activity of sale of proprietary models.

**Alexandre Fraichard, CEO of genOway, stated:** *"In 2006, we signed our first agreement in Japan with ONO Pharmaceuticals. Since our business development team has made a great job on this local market. Today, genOway is working with 4 major nippon pharma companies and has become the leading supplier of research tools in the US, in Europe and in Asia."*

#### **About genOway:**

genOway (ALTERNEXT-NYSE:ALGEN) is a biotechnology company dedicated to the development of genetically modified animal models aimed at enhancing the security and relevancy of in vivo research projects. Focusing its effort on the mouse and rat, genOway's expertise combined transgenic technologies such as pronuclear microinjection, Knock-out, Knock-in, Knock- down, point mutation, humanization combined with innovative patented technologies adapted to target validation, in vivo drug screening, drug efficacy and safety testing program. Collaborations with worldwide leaders (Charles River Laboratories, Invitrogen, Tet systems, etc..) enable genOway to provide its customer with a complete portfolio of products and services for all aspects of model generation and characterization.

Operating in 22 countries in Europe, North America and Asia, genOway has developed more than 450 rat and mouse lines for 50 companies and 175 research institutions. Thanks to its industrialized production facilities, genOway is involved in large-scale projects with several academic centers (German National Genome Research Network, University College London, King's College London, Max Planck Institute) and with pharmaceutical companies (BayerCorp, Boehringer Ingelheim, Johnson& Johnson).

For more information consult: [www.genoway.com](http://www.genoway.com)

**Contacts:**

Marie Norbert - genOway - [norbert@genoway.com](mailto:norbert@genoway.com)

Contact for investors:

Gilles de Poncins , CFO - genOway - [finances@genoway.com](mailto:finances@genoway.com)

Milestones - Press & Investors Relation

Bruno Arabian / Jean-Christophe Labastugue

Tel. : +33 170 08 04 13 / 14

E-mail : [milestones@milestones-fr.com](mailto:milestones@milestones-fr.com) / [jclabastugue@milestones.fr](mailto:jclabastugue@milestones.fr)

*Warning: This press release expressly contains, in an implicit manner, certain prospective statements concerning genOway and its activity. These statements rely on certain risks, known or unknown, uncertainty or on other factors that may lead to actual results, financial conditions, performance or achievements on the part of genOway that may differ significantly from the results, financial conditions, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to update the prospective statements contained therein, either as a result of new information, future events or other. For a description of the risks or uncertainty of a nature to cause a difference between genOway's actual results, financial conditions, performance or achievements and those contained in the prospective statements, please refer to the section on "Risk Factors" on the Prospectus available on the genOway website <http://www.genoway.com>*